Menu
ncarol.com
  • Home
  • Business
  • Financial
  • Yacht Buyer
  • Stocks
  • Finance
  • Banking
  • Nyse
  • Loans
ncarol.com

Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference
ncarol.com/10212254

Trending...
  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies
  • Still Using Ice? FrostSkin Reinvents Hydration
  • Dave Aronberg Named 2026 John C. Randolph Award Recipient by Palm Beach Fellowship of Christians & Jews
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.

Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET

The fireside chat will be available via a live webcast accessible on Precision's website in the Investors section under Events & Presentations on February 28, 2023: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.

More on ncarol.com
  • PADT Earns Prestigious 2025 Americas Customer Loyalty Award from Ansys, Part of Synopsys
  • Florida Keys Visitors Can Save 15 Percent With KeysCaribbean's Advanced Booking Discount
  • Sleep Basil Unveils Revamped Natural Latex Mattress Collection Page for Cooler, Cleaner, Better-Aligned Sleep
  • Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
  • DASH Carolina RDU Sets the Pace in 2025 with Record-Breaking Sales and Team Excellence

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple ex vivo "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

Contacts

Investor Contact:

Mei Burris
Director, Investor Relations & Finance
Mei.burris@precisionbiosciences.com

Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • PRÝNCESS Builds Anticipation With "My Nerves" — A Girls-Girl Anthem
  • Arbutus Medical Raises C$9.3M to Accelerate Growth of Surgical Workflow Solutions Outside the OR
  • From Sleepless Nights to Sold-Out Drops: Catch Phrase Poet's First Year Redefining Motivational Urban Apparel
  • Cold. Clean. Anywhere. Meet FrostSkin
  • How Specialized Game Development Services Are Powering the Next Wave of Interactive Entertainment
  • Don't Settle for a Lawyer Who Just Speaks Spanish. Demand One Who Understands Your Story
  • Dan Williams Promoted to Century Fasteners Corp. – General Manager, Operations
  • Ski Johnson Inks Strategic Deals with Three Major Food Chain Brands
  • NIL Club Advances Agent-Free NIL Model as Oversight Intensifies Across College Athletics
  • Atlanta Magazine Names Dr. Rashad Richey One of Atlanta's Most Influential Leaders in 2026 as the FIFA World Cup Approaches
  • Apostle Margelee Hylton Announces the Release of Third Day Prayer
  • Slotozilla Reports Strong Q4 Growth and Sigma Rome Success
  • "Lights Off" and Laughs On: Joseph Neibich Twists Horror Tropes in Hilariously Demonic Fashion
  • Families Gain Clarity: Postmortem Pathology Expands Private Autopsy Services in St. Louis
  • Beethoven: Music of Revolution and Triumph - Eroica
  • Amy Turner Receives 2025 ENPY Partnership Builder Award from The Community Foundation
  • The "Human Bridge": Why Leading with Tools is Failing Our Children
  • Hubble Tension Solved? Study finds evidence of an 'Invisible Bias' in How We Measure the Universe
  • Boonuspart.ee Acquires Kasiino-boonus.ee to Strengthen Its Position in the Estonian iGaming Market
  • Vines of Napa Launches Partnership Program to Bolster Local Tourism and Economic Growth
_catLbl0 _catLbl1

Popular on ncarol.com

  • Crossroads4Hope Welcomes New Trustees to Board of Directors as Organization Enters 25th Year of Caring - 118
  • Desert Mountain Club Earns Prestigious Blue Zones Approved™ Triple Designation, a New Standard for Well-Being in a Luxury Lifestyle Community
  • $80 Million Revenue Backlog for AI Cybersecurity Company Building the Future of Integrated Cybersecurity and Public Safety: $CYCU
  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies
  • Impact Futures Group expands through acquisition of specialist healthcare sector training provider Caring for Care
  • $10 Price Target in Think Equity Report Supported by Inventory Financing Floorplan Boot to $60 Million for 2026 Sales Growth in Pre-Owned Boats: $OTH
  • New Medium Article Explores Why Emotional Conversations Fail and What Most People Don't Understand About Connection
  • Powering the AI, Defense and Aerospace Future with Energy Infrastructure and Digital Asset Strength: KULR Technology Group, Inc. $KULR
  • Does EMDR Really Work? New Article Explores How Trauma Gets Stuck in the Brain and How Healing Begins
  • Postmortem Pathology Expands to Phoenix: Bringing Families Answers During Their Most Difficult Moments

Similar on ncarol.com

  • $36 Million LOI to Acquire High Value Assets from Vivakor Inc in Oklahoma's STACK Play — Building Cash Flow and Scalable Power Infrastructure; $OLOX
  • Art of Whiskey Hosts 3rd Annual San Francisco Tasting Experience During Super Bowl Week
  • FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
  • $2.7 Million 2025 Revenue; All Time Record Sales Growth; 6 Profitable Quarters for Homebuilding Industry: Innovative Designs (Stock Symbol: IVDN)
  • How Specialized Game Development Services Are Powering the Next Wave of Interactive Entertainment
  • NIL Club Advances Agent-Free NIL Model as Oversight Intensifies Across College Athletics
  • Slotozilla Reports Strong Q4 Growth and Sigma Rome Success
  • Families Gain Clarity: Postmortem Pathology Expands Private Autopsy Services in St. Louis
  • Amy Turner Receives 2025 ENPY Partnership Builder Award from The Community Foundation
  • Vines of Napa Launches Partnership Program to Bolster Local Tourism and Economic Growth
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute